Prediction of Antiglycation Activity by Calculating the Energies of Frontier Molecular Orbitals for New 4-Hydroxy-1,4-Dihydroazolo[5,1-c]-1,2,4-Triazines Used as an Example
作者:R. A. Litvinov、R. A. Drokin、D. D. Shamshina、M. Yu. Kalenova、L. E. Usmianova、E. A. Muraveva、P. M. Vasiliev、E. K. Voinkov、E. N. Ulomskiy、A. A. Spasov、V. L. Rusinov
DOI:10.1134/s1068162020060175
日期:2020.11
(aminoguanidine), antiglycation activity correlated with the energy difference ∆ (HOMO – LUMO) between the highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO); the difference was established by a PM3 semiempirical method. Artificial neural network modeling was used to develop a mathematical model that describes the dependence of antiglycation activity on the calculated energies
摘要 蛋白质糖基化和晚期糖基化终产物 (AGEs) 的形成在糖尿病 (DM) 并发症、神经退行性疾病和年龄相关疾病的发病机制中起着重要作用。预测抗糖化活性的模型可以降低成本并提高新化合物临床前筛选研究的生产力和质量。唑并[5,1-c][1,2,4]三嗪和唑并[1,5-a]嘧啶是众所周知的生物活性化合物,它们还具有抗糖化特性。选择了许多 4-hydroxy-4 H-azolo-1,4-dihydro[5.1-c]-1,2,4-triazines 来设计预测模型。发现 Azolotriazine 衍生物具有抗糖化作用,与氨基胍相比,用葡萄糖和特异性 END 荧光抑制牛血清白蛋白 (BSA) 的糖化作用,效率相同或更高。对于不同取代的衍生物,1000 μM 的活性范围估计为 23.0–71.6%(氨基胍为 30.3 ± 1.2%)。4-羟基-3-氰基-1,4-二氢-1,2,4-三唑并[5.1-c]1